← Leaderboards
David C Whitacre
Vlp Biotech, Inc.
$3,521,887
Attributed
$4,161,930
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $998.1K · FY2007–21$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$4,161,930 · 5
By mechanism
R44$2,281,843 · 1
R41$1,055,946 · 2
R43$824,141 · 2
Top collaborators
- Jon Oscherwitz4 shared
- David R. Milich1 shared
Others in their field
Top investigators on “Vaccines”
- Lawrence Corey · Fred Hutchinson Cancer Center$829,044,908
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$556,540,832
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$515,215,260
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
- Dennis R. Burton · Scripps Research Institute$316,106,418
Research focus
VaccinesAntibodiesEpitopesImmunogenicTechnologyAntigensDoseVirus-Like ParticleDesignImmunizationAdjuvantNeutralizing AntibodyToxinAnthrax DiseaseAerosolsProtocols DocumentationBacillus AnthracisNonhuman PrimateOryctolagus CuniculusImmunogenicityImmune SeraProductionSpecificityEngineering
Grant awards (10)
An epitope-focused nanoparticle vaccine for anthrax$983,698
R44 · FY2021 · AI · contact PI
An epitope-focused nanoparticle vaccine for anthrax$998,145
R44 · FY2020 · AI · contact PI
An epitope-focused nanoparticle vaccine for anthrax$300,000
R44 · FY2019 · AI · contact PI
An epitope-focused nanoparticle vaccine for MRSA and biodefense$272,381
R41 · FY2017 · AI
An epitope-focused nanoparticle vaccine for MRSA and biodefense$273,748
R41 · FY2016 · AI
An Epitope-Focused Pediatric RSV Vaccine$224,141
R43 · FY2016 · AI
A molecularly targeted pre- and post-exposure vaccine for anthrax$249,612
R41 · FY2015 · AI
A molecularly targeted pre- and post-exposure vaccine for anthrax$260,205
R41 · FY2014 · AI
Development of a Proplylactic HCV Vaccine$300,000
R43 · FY2008 · AI · contact PI
Development of a Proplylactic HCV Vaccine$300,000
R43 · FY2007 · AI · contact PI